查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1729635

日本放射治療市場規模、佔有率、趨勢及預測（按類型、應用、最終用戶和地區），2025 年至 2033 年

Japan Radiotherapy Market Size, Share, Trends and Forecast by Type, Application, End User, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 122 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

2024 年日本放射治療市場規模價值 4.4437 億美元。展望未來， IMARC Group估計到 2033 年市場規模將達到 7.1947 億美元，2025 年至 2033 年的複合年成長率為 5.28%。治療方式的不斷突破、強調老年醫療保健的人口趨勢、促進先進醫療保健的政策措施、醫療保健投資的快速擴張以及公眾對早期干預的認知的不斷提高，正在顯著影響日本放射治療市場佔有率。

日本市場主要受到能夠實現更準確、更有針對性的放射治療的進步和創新的推動。例如，2024年5月30日，日本國家量子科學技術研究所（QST）宣布成功透過雷射照射產生高能量電子束，這項突破可望改善放射癌症治療。此項開發利用微毛細管板產生高效率電子束，可減少輻射暴露並消除屏蔽的需要。這項創新為低成本內視鏡放射治療鋪平了道路，並有望應用於癌症治療。除此之外，人工智慧 (AI) 和機器學習在放射治療計劃和實施中的整合最佳化了治療工作流程和結果，為市場提供了動力。此外，日本擁有高技能的醫療專業人員和完善的醫療保健系統，確保這些治療能夠有效率地進行，從而促進市場擴張。此外，領先企業和學術機構正在進行的研究和開發 (R&D) 活動正在促進放射治療領域的創新，豐富日本放射治療市場的前景。

此外，包括專門的腫瘤中心在內的醫療保健基礎設施的投資不斷增加，使得全國各地都能輕鬆獲得放射治療服務。此外，大眾對早期癌症診斷和治療方案的認知不斷提高，導致產品使用率更高。除此之外，國內外公司的合作正在促進技術進步和市場競爭力，從而確保日本放射治療解決方案的可用性。例如，2024 年 1 月 17 日，Vysioneer 宣布與 MC Medical 達成策略合作，將其基於人工智慧的腦腫瘤自動勾畫解決方案 VBrain 引入日本市場。此次合作旨在利用人工智慧技術增強臨床工作流程並提高腦腫瘤管理的​​治療精度。 VBrain 旨在簡化臨床工作流程並提高腦放射外科和放射治療的治療準確性，從而顯著減少工作量並提高患者護理品質。

日本放射治療市場趨勢：

癌症發生率上升和人口老化

癌症發生率的不斷上升，尤其是在日本老齡化人口中，正在影響日本放射治療市場的成長。日本國立醫學圖書館的一項研究表明，日本癌症的總體發病率可能會上升。預計到 2050 年，新發病例總數將達到 3,665,900（3,210,200 至 4,201,400）千例，比 2020 年增加 13.1%。人口趨勢也增加了醫療基礎設施投資和重要放射治療技術的實施。這一成長也歸因於75歲及以上老年人口的成長。罹患癌症的風險會隨著年齡的成長而增加，因此對放射治療等更先進的治療方式的需求也在增加。這些治療的進步旨在提高治療的精確度、最大限度地減少副作用並滿足老年患者的獨特需求。

放射治療設備的技術進步

技術進步正在顯著提升日本放射治療市場的佔有率。影像導引放射治療 (IGRT)、調強放射治療 (IMRT)、立體定位放射治療 (SBRT) 等放射治療設備創新提高了治療的準確性，同時減少了對周圍組織的損傷。日本在質子和重離子治療系統的開發方面處於領先地位，這些系統對複雜的腫瘤治療非常有效。這些創新透過將患者與政府加強內部醫療保健能力的措施相結合，滿足了患者日益成長的需求。例如，2024年，日立高新技術推出了OXRAY，這是一款X光治療系統，旨在減輕患者負擔，同時為癌症提供精準的放射治療。該系統的攜帶式設計允許安裝在專門的醫療中心和地區醫院，為癌症治療帶來精確性和高品質。日立高新技術正在開發先進的粒子束系統和加速器，用於高精度、低成本的治療，進一步增強患者友善、高精度的癌症治療。隨著越來越多的醫院和癌症中心利用這些創新，這些發展推動了市場需求。

政府政策和醫療基礎設施擴張

醫療政策和基礎設施投資影響日本放射治療市場趨勢。日本主要透過《癌症控制法》致力於癌症患者的護理，強調早期發現、標準化治療和採用先進技術。政府投入大量資金更新醫療保健結構並增加癌症專門治療的可用性。這些措施得到了厚生勞動省的支持，以促進臨床試驗和研究，從而推動放射治療的創新發展。戰略合作夥伴關係促進了先進放射治療技術的應用，並推動了支持市場擴張的投資。例如，2024 年 9 月 24 日，國際原子能總署 (IAEA)、宏都拉斯和日本政府透過國際原子能總署的「希望之光」計劃合作，促進洪都拉斯的癌症治療。此次合作將增加放射治療服務，並擴大宏都拉斯獲得挽救生命的癌症診斷和治療的機會。為此，日本政府表示有興趣提供設施、設備和基礎設施。同時，國際原子能總署將提供技術諮詢服務，促進該國增加放射學、核子醫學和放射治療設施。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：日本放射治療市場-簡介

  • 概述
  • 市場動態
  • 產業趨勢
  • 競爭情報

第5章：日本放射治療市場格局

  • 歷史與當前市場趨勢（2019-2024）
  • 市場預測（2025-2033）

第6章：日本放射治療市場-分類：依類型

  • 體外放射治療
    • 概述
    • 市場區隔
      • 調強放射治療 (IMRT)
      • 影像導引放射治療 (IGRT)
      • 斷層治療
      • 立體定位放射外科
      • 立體定位放射治療
      • 質子治療
      • 3D適形放射治療（3D CRT）
      • 容積調強弧形治療 (VMAT)
  • 內部放射治療/近距離放射治療
    • 概述
  • 全身放射治療
    • 概述

第7章：日本放射治療市場-細分：依應用

  • 皮膚和唇癌
    • 概述
  • 頭頸癌
    • 概述
  • 乳癌
    • 概述
  • 攝護腺癌
    • 概述
  • 子宮頸癌
    • 概述
  • 肺癌
    • 概述
  • 其他

第 8 章：日本放射治療市場 - 細分：按最終用戶

  • 醫院
    • 概述
  • 癌症研究機構
    • 概述
  • 門診及放射治療中心
    • 概述

第9章：日本放射治療市場-競爭格局

  • 概述
  • 市場結構
  • 市場參與者定位
  • 最佳獲勝策略
  • 競爭儀錶板
  • 公司評估象限

第10章：關鍵參與者簡介

  • Elekta K.K. (Elekta)
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Hitachi Ltd.
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Osaka Heavy Ion Therapy Center
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Sumitomo Heavy Industries Ltd.
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Toshiba Corporation
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第 11 章：日本放射治療市場-產業分析

  • 促進因素、限制因素和機遇
    • 概述
    • 驅動程式
    • 限制
    • 機會
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
  • 價值鏈分析

第 12 章：附錄

簡介目錄
Product Code: SR112025A18341

The Japan radiotherapy market size was valued at USD 444.37 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 719.47 Million by 2033, exhibiting a CAGR of 5.28% from 2025-2033. Continual breakthroughs in treatment modalities, demographic trends emphasizing senior healthcare, policy measures promoting advanced medical care, rapid expansion of healthcare investments, and the growing public awareness regarding early interventions are impacting the Japan radiotherapy market share significantly.

The market in Japan is primarily driven by the advancements and innovations that enable more accurate and targeted radiotherapy. For example, on May 30, 2024, the National Institute for Quantum Science and Technology (QST) announced the successful generation of high-energy electron beams via laser irradiation, a breakthrough expected to improve radiation cancer treatment. This development uses microcapillary plates to produce efficient electron beams, which could reduce radiation exposure and eliminate the need for shielding. The innovation paves the way for low-cost, endoscopic radiation therapy with potential applications in cancer treatment. Besides this, the integration of artificial intelligence (AI) and machine learning in radiotherapy planning and delivery has optimized treatment workflows and outcomes, which is providing an impetus to the market. Furthermore, the presence of highly skilled medical professionals and a well-established healthcare system in Japan ensures efficient delivery of these treatments, which is facilitating market expansion. Also, ongoing research and development (R&D) activities by leading players and academic institutions are fostering innovations in radiotherapy is enriching the Japan radiotherapy market outlook.

In addition to this, the increasing investments in healthcare infrastructure, including specialized oncology centers, are enabling easy accessibility of radiotherapy services across the country. Moreover, the rising awareness among the public regarding early cancer diagnosis and treatment options is leading to a higher product uptake. Apart from this, collaborations between domestic and international companies are encouraging technological advancements and market competitiveness, thereby ensuring the availability of radiotherapy solutions in Japan. For instance, on January 17, 2024, Vysioneer announced a strategic collaboration with MC Medical to introduce its AI-powered brain tumor auto-contouring solution, VBrain, to the Japanese market. This partnership aims to enhance clinical workflows and improve treatment precision in brain tumor management by leveraging AI technology. VBrain is designed to streamline clinical workflows and elevate treatment accuracy for brain radiosurgery and radiotherapy, offering significant reductions in workload and improvements in patient care quality.

Japan Radiotherapy Market Trends:

Rising Prevalence of Cancer and Aging Population

The increasing incidence of cancer, especially among Japan's aging population, is impacting the Japan radiotherapy market growth. A research conducted by the National Library of Medicine indicates that the overall incidence of cancer in Japan is likely to rise. It estimates a total of 3,665,900 (3,210,200 to 4,201,400) thousand new cases by 2050, indicating a 13.1% increase from the year 2020. The demographic trend has also increased healthcare infrastructure investment and the implementation of significant radiotherapy technologies. The increase is also attributed to aging people aged 75 years and older. The risk of cancer increases with age, and thus, the demand for more advanced treatment modalities, such as radiotherapy, is increasing. These advances in treatment are meant to improve precision, minimize side effects, and cater to the unique needs of older patients.

Technological Advancements in Radiotherapy Equipment

Technological progress is significantly rising the Japan radiotherapy market share. Radiotherapy equipment innovations such as image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and stereotactic body radiotherapy (SBRT) improve the accuracy of treatment while reducing damage to surrounding tissues. Japan leads the way in developing proton and heavy ion therapy systems, which are highly effective in complex tumor treatments. The innovations cater to the increasing requirements of patients by aligning them with government measures to enhance internal healthcare capabilities. For instance, in 2024, Hitachi High-Tech released OXRAY, an X-ray therapy system designed to reduce patient burdens while delivering accurate radiation treatment for cancer. The portable design of this system allows installation at specialized medical centers and regional hospitals, bringing precision and quality to cancer treatments. Hitachi High-Tech is developing advanced particle beam systems and an accelerator for high-precision, low-cost treatments, further enhancing patient-friendly, high-precision cancer therapies. These developments drive the market demand as more hospitals and cancer centers leverage these innovations.

Government Policies and Healthcare Infrastructure Expansion

Healthcare policies and infrastructural investments influence Japan radiotherapy market trends. Japan mainly focuses its efforts on the care of cancer patients through its Cancer Control Act, underlining early detection, standardization of treatment, and the adoption of advanced technology. The government invests heavily in updating healthcare structures and increasing the availability of specialized treatments for cancer. These initiatives are followed by the support given by the Ministry of Health, Labour, and Welfare in promoting clinical trials and research, hence the development of innovations in radiotherapy. Strategic partnerships foster the adoption of advanced radiotherapy technologies and drive investments that support market expansion. For instance, on 24 September 2024, the International Atomic Energy Agency (IAEA), Honduras, and the Government of Japan collaborated to promote cancer care in Honduras through the IAEA's Rays of Hope initiative. This collaboration will increase radiotherapy services and extend access to lifesaving cancer diagnosis and treatment in Honduras. For this, the government of Japan has expressed its interest to contribute with facilities, equipment, and infrastructures. At the same time, the IAEA will provide technical advisory services to foster an increase in the country's facilities for radiology, nuclear medicine, and radiotherapy.

Japan Radiotherapy Industry Segmentation:

Analysis by Type:

  • External Beam Radiation Therapy
    • Intensity-Modulated Radiation Therapy (IMRT)
    • Image-Guided Radiation Therapy (IGRT)
    • Tomotherapy
    • Stereotactic Radiosurgery
    • Stereotactic Body Radiation Therapy
    • Proton Therapy
    • 3D Conformal Radiotherapy (3D CRT)
    • Volumetric Modulated Arc Therapy (VMAT)
  • Internal Radiation Therapy/Brachytherapy
  • Systemic Radiation Therapy

External beam radiation therapy (EBRT) is a significant segment in the radiation therapy market in Japan. EBRT helps give high-energy beams targeted toward tumors but minimizes damage to other tissues around it. Advances like intensity-modulated radiation therapy (IMRT) and SBRT are gradually used for greater precision and decreased side effects of radiation. Japan's investment in cutting-edge linear accelerators and image-guided technologies enhances treatment outcomes. With an aging population and increasing cancer incidence, EBRT remains essential in expanding access to non-invasive and effective treatment solutions.

Brachytherapy is one of the key components of radiotherapy advancements in Japan, especially for cervical, prostate, and breast cancers. The radioactive sources are placed directly inside or near the tumor, delivering high doses of radiation to the target while sparing healthy tissues. This approach allows for shorter treatment durations and fewer hospital visits, appealing to patient preferences. Japan's adoption of image-guided brachytherapy (IGBT) has significantly improved accuracy and outcomes. Government-sponsored programs to incorporate brachytherapy into overall cancer treatment emphasize the role of brachytherapy, especially in areas where high-tech external beam technologies are scarce.

Systemic radiation therapy, including radiopharmaceuticals, has been increasingly adopted in Japan, especially for metastatic cancers. The therapy is delivered through radioactive drugs that circulate in the bloodstream to reach the cancer cells. Lutetium-177 and Iodine-131 are the most common radionuclides used for prostate and thyroid cancers, respectively. In Japan, improvements in the regulatory side have allowed more rapid approvals for radiopharmaceuticals, thus growing the market. Systemic therapy would represent a minimally invasive treatment modality with specificity, as advocated by personalized medicine in Japan, improving patient quality of life.

Analysis by Application:

  • Skin and Lip Cancer
  • Head and Neck Cancer
  • Breast Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Lung Cancer
  • Others

Radiotherapy plays an important role in the management of skin and lip cancer in Japan, especially non-melanoma types such as basal cell carcinoma and squamous cell carcinoma. For tumors in cosmetically sensitive areas, external beam radiation therapy (EBRT) is widely used to avoid surgery. Techniques like superficial X-ray therapy and brachytherapy provide targeted therapy with minimal scarring and excellent aesthetic results. The management is effective due to the increasing awareness regarding early diagnosis and the availability of advanced technologies.

Radiotherapy is significant in the treatment of head and neck cancers in Japan, and is usually combined with chemotherapy or surgery to achieve better results. These cancers, involving the oral cavity, pharynx, and larynx, need specific targeting to conserve vital structures. Technologies such as intensity-modulated radiation therapy and image-guided radiation therapy have become widely used, where the tumor would be controlled in the least aggressive manner possible in terms of side effects such as xerostomia and swallowing difficulty. Japan also invests in proton therapy in support of good care.

Radiotherapy is used in Japan after lumpectomy as the first treatment course for breast cancer, minimizing the risks of recurrence. It also applies different techniques like whole-breast irradiation and APBI tailored to each patient, achieving efficient tumor control while avoiding excessive damage to normal tissues. Advanced technologies employed include 3D conformal radiation and proton therapy, which take accurate targeting, more so for left-sided breast cancer exposure on the heart. The rise in breast cancer diagnoses in Japan is one of the major Japan radiotherapy market trends that are leading to increased investment in radiotherapy infrastructure to drive the care of the disease and thus increase survival rates.

Analysis by End User:

  • Hospitals
  • Cancer Research Institutes
  • Ambulatory and Radiotherapy Centers

Hospitals are the biggest players in Japan's radiotherapy market. As a single point stop for all cancer treatment needs, hospitals have well-equipped technologies like linear accelerators and proton therapy systems. These centers provide high-quality care to patients through the administration of EBRT and brachytherapy, thus being able to guarantee accuracy and patient safety. Since cancer is one of the leading causes of death in Japan, hospitals increasingly integrate radiotherapy with surgical and systemic treatments. Government investments in public hospitals to expand radiotherapy infrastructure and improve accessibility underline their central role in meeting the growing demand for advanced cancer care.

Radiotherapy technologies and techniques are advanced in Japan by research institutes dedicated to cancer. Such institutes are oriented toward clinical trials, including novel approaches such as proton and carbon-ion therapy and personalized medicine solutions. Their contribution increases the effectiveness of treatment, reduces side effects, and enhances survival rates. Collaboration with academic and industrial partners propels innovative radiopharmaceuticals and diagnostic tools into the future. These institutes support Japan's leadership in radiotherapy innovation and contribute to global advancements in cancer treatment strategies by training specialized professionals and conducting research on treatment optimization.

Ambulatory and radiotherapy centers are growing in popularity in Japan, catering to the needs of accessible, specialized cancer care. These are outpatient centers, thus reducing pressure on hospitals and, at the same time, providing high-quality care. They are fitted with the most advanced systems of EBRT and brachytherapy, so precise and efficient care is assured. Their operations are streamlined, and the treatment is shorter, a factor that attracts patients who desire convenience. Also, due to the increasing incidence of cancer and an aging population, these centers will be crucial for decentralizing care and meeting the demand, particularly in areas that lack comprehensive hospital facilities.

Competitive Landscape:

The market in Japan is highly competitive, majorly driven by technological advancements and innovation. Key players focus more on the development of precision-based radiotherapy systems such as proton and carbon ion therapy to address the increasing cancer burden. Higher investments in research and development (R&D) activities and healthcare infrastructure expansion also intensify competition. Strategic partnerships among healthcare institutions and technology developers help to foster innovation and accelerate the adoption of next-generation radiotherapy equipment. These partnerships improve accessibility to advanced treatments while ensuring market growth. For instance, on 31 October 2024, Leo Cancer Care announced a partnership with Anzai Medical Co., Ltd, making Anzai the official distributor of Leo's upright radiation therapy systems in Japan. This collaboration aims to enhance patient comfort and treatment efficiency by introducing new systems, which include the Marie upright particle therapy solution. The partnership will provide Japanese healthcare providers with state-of-the-art, adaptable radiation therapy technologies in line with the commitment of both companies to enhance cancer care.

The report provides a comprehensive analysis of the competitive landscape in the Japan radiotherapy market with detailed profiles of all major companies, including:

  • Elekta K.K. (Elekta)
  • Hitachi Ltd.
  • Osaka Heavy Ion Therapy Center
  • Sumitomo Heavy Industries Ltd.
  • Toshiba Corporation

Latest News and Developments:

  • April 17, 2024: Japan's National Institutes for Quantum Science and Technology (QST) initiated multi-ion heavy particle radiotherapy to enhance cancer treatment, particularly for bone and soft-tissue sarcoma. This next-generation technology combines ion beams like carbon, oxygen, and helium for tailored treatment, reducing side effects and improving efficacy. The development, achieved in collaboration with Sumitomo Heavy Industries, builds on three decades of advancements and positions Japan as a leader in radiotherapy innovation.
  • June 18, 2024: RaySearch Laboratories' RayStation was used for the world's first clinical radiotherapy treatment with Hitachi's OXRAY system at Narita Memorial Hospital in Toyohashi, Japan. OXRAY, developed in collaboration with Kyoto University Hospital, integrates a Gimbal-mounted beam delivery system and advanced motion tracking capabilities, improving precision and flexibility in radiotherapy. This milestone highlights the synergy between RaySearch's planning software and OXRAY's innovative technology, promising enhanced treatment outcomes.
  • June 27, 2024: Yamagata University's East Japan Heavy Ion Center, offering advanced carbon-ion radiation therapy, is becoming a key hub for medical tourism. The facility specializes in treating various cancers with minimal side effects, attracting both domestic and international patients. The center is expanding its collaborations with local businesses to offer tailored travel and treatment packages, boosting the region's economy through medical tourism.
  • September 25, 2024: Leo Cancer Care announced a new research partnership with QST Hospital in Japan to test its upright positioning system for cancer treatment. This collaboration aims to evaluate patient comfort, reproducibility, and immobilization across various anatomical regions, with a focus on advancing carbon ion radiotherapy. The partnership follows similar agreements in Japan and Italy, marking significant progress in the development of upright radiotherapy solutions.

Key Questions Answered in This Report

  • 1.How big is the radiotherapy market in Japan?
  • 2.What factors are driving the growth of Japan radiotherapy market?
  • 3.What is the forecast for the radiotherapy market in Japan?
  • 4.Who are the major players in the radiotherapy market in Japan?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Radiotherapy Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Radiotherapy Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Radiotherapy Market - Breakup by Type

  • 6.1 External Beam Radiation Therapy
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Intensity-Modulated Radiation Therapy (IMRT)
      • 6.1.3.2 Image-Guided Radiation Therapy (IGRT)
      • 6.1.3.3 Tomotherapy
      • 6.1.3.4 Stereotactic Radiosurgery
      • 6.1.3.5 Stereotactic Body Radiation Therapy
      • 6.1.3.6 Proton Therapy
      • 6.1.3.7 3D Conformal Radiotherapy (3D CRT)
      • 6.1.3.8 Volumetric Modulated Arc Therapy (VMAT)
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Internal Radiation Therapy/Brachytherapy
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Systemic Radiation Therapy
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Forecast (2025-2033)

7 Japan Radiotherapy Market - Breakup by Application

  • 7.1 Skin and Lip Cancer
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Head and Neck Cancer
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)
  • 7.3 Breast Cancer
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2019-2024)
    • 7.3.3 Market Forecast (2025-2033)
  • 7.4 Prostate Cancer
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2019-2024)
    • 7.4.3 Market Forecast (2025-2033)
  • 7.5 Cervical Cancer
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2019-2024)
    • 7.5.3 Market Forecast (2025-2033)
  • 7.6 Lung Cancer
    • 7.6.1 Overview
    • 7.6.2 Historical and Current Market Trends (2019-2024)
    • 7.6.3 Market Forecast (2025-2033)
  • 7.7 Others
    • 7.7.1 Historical and Current Market Trends (2019-2024)
    • 7.7.2 Market Forecast (2025-2033)

8 Japan Radiotherapy Market - Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2019-2024)
    • 8.1.3 Market Forecast (2025-2033)
  • 8.2 Cancer Research Institutes
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2019-2024)
    • 8.2.3 Market Forecast (2025-2033)
  • 8.3 Ambulatory and Radiotherapy Centers
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2019-2024)
    • 8.3.3 Market Forecast (2025-2033)

9 Japan Radiotherapy Market - Competitive Landscape

  • 9.1 Overview
  • 9.2 Market Structure
  • 9.3 Market Player Positioning
  • 9.4 Top Winning Strategies
  • 9.5 Competitive Dashboard
  • 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

  • 10.1 Elekta K.K. (Elekta)
    • 10.1.1 Business Overview
    • 10.1.2 Services Offered
    • 10.1.3 Business Strategies
    • 10.1.4 SWOT Analysis
    • 10.1.5 Major News and Events
  • 10.2 Hitachi Ltd.
    • 10.2.1 Business Overview
    • 10.2.2 Services Offered
    • 10.2.3 Business Strategies
    • 10.2.4 SWOT Analysis
    • 10.2.5 Major News and Events
  • 10.3 Osaka Heavy Ion Therapy Center
    • 10.3.1 Business Overview
    • 10.3.2 Services Offered
    • 10.3.3 Business Strategies
    • 10.3.4 SWOT Analysis
    • 10.3.5 Major News and Events
  • 10.4 Sumitomo Heavy Industries Ltd.
    • 10.4.1 Business Overview
    • 10.4.2 Services Offered
    • 10.4.3 Business Strategies
    • 10.4.4 SWOT Analysis
    • 10.4.5 Major News and Events
  • 10.5 Toshiba Corporation
    • 10.5.1 Business Overview
    • 10.5.2 Services Offered
    • 10.5.3 Business Strategies
    • 10.5.4 SWOT Analysis
    • 10.5.5 Major News and Events

11 Japan Radiotherapy Market - Industry Analysis

  • 11.1 Drivers, Restraints and Opportunities
    • 11.1.1 Overview
    • 11.1.2 Drivers
    • 11.1.3 Restraints
    • 11.1.4 Opportunities
  • 11.2 Porters Five Forces Analysis
    • 11.2.1 Overview
    • 11.2.2 Bargaining Power of Buyers
    • 11.2.3 Bargaining Power of Suppliers
    • 11.2.4 Degree of Competition
    • 11.2.5 Threat of New Entrants
    • 11.2.6 Threat of Substitutes
  • 11.3 Value Chain Analysis

12 Appendix